Dubuque Bank & Trust Co. trimmed its stake in shares of Pfizer Inc. (NYSE:PFE – Get Rating) by 0.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,256 shares of the biopharmaceutical company’s stock after selling 317 shares during the period. Dubuque Bank & Trust Co.’s holdings in Pfizer were worth $1,848,000 at the end of the most recent reporting period.
A number of other large investors also recently modified their holdings of PFE. Aureus Asset Management LLC acquired a new position in shares of Pfizer during the fourth quarter worth approximately $221,000. Nuveen Asset Management LLC raised its stake in shares of Pfizer by 18.0% during the fourth quarter. Nuveen Asset Management LLC now owns 28,086,667 shares of the biopharmaceutical company’s stock worth $1,658,518,000 after buying an additional 4,278,167 shares during the last quarter. Gordian Capital Singapore Pte Ltd bought a new stake in shares of Pfizer during the fourth quarter worth approximately $237,000. Odey Asset Management Group Ltd raised its stake in shares of Pfizer by 85.7% during the fourth quarter. Odey Asset Management Group Ltd now owns 130,000 shares of the biopharmaceutical company’s stock worth $7,677,000 after buying an additional 60,000 shares during the last quarter. Finally, Banco de Sabadell S.A raised its stake in shares of Pfizer by 16.7% during the fourth quarter. Banco de Sabadell S.A now owns 47,358 shares of the biopharmaceutical company’s stock worth $2,797,000 after buying an additional 6,793 shares during the last quarter. 67.90% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on the stock. Barclays set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. SVB Leerink dropped their price target on shares of Pfizer from $55.00 to $53.00 and set a “market perform” rating for the company in a research note on Friday, July 29th. The Goldman Sachs Group set a $50.00 price target on shares of Pfizer in a research note on Thursday, September 1st. JPMorgan Chase & Co. set a $57.00 target price on shares of Pfizer in a research note on Tuesday, June 28th. Finally, UBS Group set a $59.00 target price on shares of Pfizer in a research note on Thursday, September 1st. Nine analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $57.00.
Pfizer Stock Performance
Pfizer (NYSE:PFE – Get Rating) last announced its earnings results on Thursday, July 28th. The biopharmaceutical company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.95 by $0.09. Pfizer had a net margin of 28.92% and a return on equity of 43.18%. The business had revenue of $27.74 billion during the quarter, compared to analysts’ expectations of $26.20 billion. During the same quarter in the prior year, the company posted $1.07 earnings per share. The firm’s revenue was up 46.8% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 6.54 EPS for the current fiscal year.
Pfizer Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 5th. Investors of record on Friday, November 4th will be issued a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 3.59%. Pfizer’s payout ratio is 31.31%.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Is The Golden Age Of Homebuilding Already Over?
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.